KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The percentages of CD3−CD16brCD56dim NK cells expressing activating receptors NKG2D, NKp30, and DNAM-1 (but not 2B4), all reduced substantially in newly diagnosed CML patients (Figure 1A).